Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,209,502 papers from all fields of science
Search
Sign In
Create Free Account
milameline
Known as:
1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxaldehyde O-methyloxime monohydrochloride
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
CI 979
Broader (2)
Dihydropyridines
Oximes
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI
Disha Shah
,
I. Blockx
,
+6 authors
A. V. D. Linden
NeuroImage
2015
Corpus ID: 17582574
Highly Cited
2005
Highly Cited
2005
Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats
C. Jones
,
E. L. Eberle
,
David B. Shaw
,
D. McKinzie
,
H. Shannon
Journal of Pharmacology and Experimental…
2005
Corpus ID: 11847787
Prepulse inhibition (PPI) of the acoustic startle reflex is a sensorimotor gating process known to be deficient in a number of…
Expand
Highly Cited
2003
Highly Cited
2003
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
C. Jack
,
M. Slomkowski
,
+9 authors
R. Petersen
Neurology
2003
Corpus ID: 21609434
Objective: To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic…
Expand
Highly Cited
2000
Highly Cited
2000
Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial
K. Rockwood
,
D. Strang
,
C. MacKnight
,
R. Downer
,
J. Morris
Journal of the American Geriatrics Society
2000
Corpus ID: 31522657
OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial.
Review
1999
Review
1999
Acetylcholinesterase inhibitors in Alzheimer's disease.
B. McGleenon
,
K. Dynan
,
A. Passmore
British journal of clinical pharmacology
1999
Corpus ID: 44963058
Alzheimer’s Disease (AD) is the most common single cause of dementia in our ageing society. Traditionally thought of as an…
Expand
Highly Cited
1999
Highly Cited
1999
Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
H. Shannon
,
J. Hart
,
+9 authors
Michael D B Swedberg
The Journal of pharmacology and experimental…
1999
Corpus ID: 5174976
The purpose of our studies was to determine the effects of muscarinic receptor agonists on conditioned avoidance responding in…
Expand
1999
1999
In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
J. Watson
,
A. J. Hunter
,
A. Brown
,
D. Middlemiss
European journal of pharmacology
1999
Corpus ID: 44804543
1999
1999
Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys
M. Callahan
Psychopharmacology
1999
Corpus ID: 25387701
Abstract Rationale: Cholinomimetic therapy in Alzheimer’s disease (AD) has been hampered by narrow efficacious dose ranges and…
Expand
1999
1999
Muscarinic Receptor Agonists in Alzheimer’s Disease
A. Fisher
1999
Corpus ID: 68661103
Research into and development of selective muscarinic receptor agonists for the treatment of Alzheimer’s disease is based on the…
Expand
Highly Cited
1998
Highly Cited
1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
F. Bymaster
,
P. Carter
,
+12 authors
P. Sauerberg
Brain Research
1998
Corpus ID: 27857418
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE